報價延遲最少15分鐘:2025/05/31 21:17 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.54 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.95/2.24
|
|
企業價值
1.48B
|
| 資產負債 |
|
每股賬面淨值
10.31
|
| 現金流量 |
|
現金流量率
0.15
|
| 損益表 |
|
收益
358.71M
|
|
每股收益
4.63
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 21:17 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. |